Nathan H. Fowler, MD - A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care - a podcast by PVI, PeerView Institute for Medical Education
from 2019-07-24T18:00
Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education